Recession coverage

Gingival recession is extremely common and can lead to complications such as root caries, compromised esthetic appearance, reduced oral hygiene and root surface hypersensitivity.1,2

Autogenous soft tissue grafts, such as free gingival grafts or connective tissue grafts, have proven successful in covering recession defects.1 However, harvesting those grafts, usually from the palate, is painful, technically demanding, time consuming and may lead to complications such as bleeding, pain, swelling, and occasionally also numbness or infections.3-6

Geistlich Fibro-Gide® or Geistlich Mucograft® combined with a coronally advanced flap or in minimal invasive techniques represent a viable alternative to recession coverage with an autologous graft.7,8 As their use spares creating a second surgical site, collagen matrices such as Geistlich Mucograft® or Geistlich Fibro-Gide® are associated with less chair time, patient pain perception and lower patient morbidity.10-12


Geistlich Fibro-Gide® is not yet available in all countries. Please contact your local Geistlich specialist on 1800 776 326 in Australia and 0800 776 326 in NZ to find out more. 


  1. Chambrone L, et al.: Cochrane Database Syst Rev (2): CD007161. (systematic review)
  2. Bignozzi I, et al.: J Periodontal Res. 2014; 49(2): 143-63. (review)
  3. Griffin TJ, et al.: J Periodontol 2006; 77: 2070-79. (clinical study)
  4. Soileau KM, et al.: J Periodontol 2006; 77: 1267-73. (clinical study)
  5. Zucchelli G, et al.: J Clin Periodontol 2010; 37: 728-38. (clinical study)
  6. Cairo F, et al.: J Clin Periodontol 2012; 39: 760-68. (clinical study)
  7. McGuire MK & Scheyer ET: J Periodontol 2016; 87(3): 221-7.
  8. Cardaropoli D, et al.: J Periodontol 2012; 83(3): 321-28.
  9. Griffin TJ, et al.: J Periodontol 2006; 77: 2070-79. (clinical study)
  10. Sanz M, et al.: J Clin Periodontol 2009; 36(10): 868-76. (clinical study)
  11. Geistlich Mucograft® Seal Advisory Board Meeting Report, 2013. Data on file, Geistlich Pharma AG, Wolhusen, Switzerland.
  12. Lorenzo R, et al.: Clin Oral Impl Res 2012; 23(3): 316-24. (clinical study)
Verena Vermeulen
Group Lead Clinical Marketing